Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 10/20 | 0.58 |
| ▸ | PLG | P00747 | 4/20 | 0.55 |
| ▸ | PLAU | P00749 | 4/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233400 | 0.99 | CHEK2 (0.58) | CHEK2PLGPLAUHDAC6HDAC3 | |
| SCHEMBL16586792 | 0.90 | CHEK2 (0.57) | CHEK2PLGPLAUHDAC6ACHE | |
| SCHEMBL12888578 | 0.88 | CHEK2 (0.55) | CHEK2PLGPLAUHDAC6 | |
| SCHEMBL20982733 | 0.82 | CHEK2 (0.58) | CHEK2HDAC6 | |
| SCHEMBL23449071 | 0.79 | CHEK2 (0.54) | CHEK2PLGPLAUHDAC6 | |
| SCHEMBL12903464 | 0.78 | CHEK2 (0.57) | CHEK2HDAC6 | |
| SCHEMBL16586719 | 0.77 | PLG (0.52) | CHEK2PLGPLAUHDAC6HDAC3 | |
| SCHEMBL1232791 | 0.76 | PLG (0.51) | CHEK2PLGPLAUHDAC6HDAC3 | |
| SCHEMBL7334131 | 0.76 | PLG (0.66) | CHEK2PLGPLAUHDAC6 | |
| SCHEMBL7333360 | 0.75 | PLG (0.62) | CHEK2PLGPLAUHDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920014-B2 | Selective inhibition of bacterial topoisomerase I | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160229810-A1 | Selective Inhibition of Bacterial Topoisomerase I | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2015042438-A1 | SELECTIVE INHIBITION OF BACTERIAL TOPOISOMERASE I | THE FLORIDA INTERNATIONAL BOARD OF TRUSTEES MODESTO A. MAIDIQUE CAMPUS (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229810-A1 | Selective Inhibition of Bacterial Topoisomerase I | TOP1, TOP2B, TOP2A | CHEK2 259/4885PLG 4101/4885PLAU 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.